Business Context and Reporting Period
This Form 8-K Current Report is filed by Spruce Biosciences, Inc. (SPRB) on March 16, 2026. The filing discloses the termination of a material definitive agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") regarding the development and commercialization of tildacerfont for congenital adrenal hyperplasia (CAH) in Japan.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity metrics. It references historical financial terms of the terminated agreement:
- Upfront Payment Received: $15.0 million (non-refundable, received in April 2023).
- Unearned Milestone Payments: Up to approximately $65.0 million (potential aggregate value at the time of the original agreement).
- Termination Penalties: $0 (no early termination penalties incurred).
Material Changes Versus Prior Period
The primary material change is the mutual termination of the Collaboration and License Agreement dated January 5, 2023, effective March 31, 2026. Consequently:
- All licenses and rights granted to Kaken for tildacerfont in Japan are terminated.
- The Company will not receive any previously disclosed unearned milestone payments or royalties from Kaken.
- The Company retains the rights to the tildacerfont program for CAH following the termination.
Guidance, Outlook, and Risks
Management Commentary: The termination follows a comprehensive assessment of the tildacerfont program for the treatment of CAH. The decision was made by mutual agreement between the parties.
Risks and Contingencies: The immediate financial impact is the forfeiture of potential future milestone payments (up to $65.0 million) and royalties. The filing does not provide updated financial guidance or specific details on the Company's future commercialization strategy for tildacerfont outside of Japan.
Investor Verification Checklist
- Verify the Company's current cash position and runway following the loss of potential future milestone revenue.
- Confirm the Company's revised strategy for the development and commercialization of tildacerfont for CAH.
- Review subsequent filings for any new partnership agreements or funding activities related to the tildacerfont program.
- Assess the impact of this termination on the Company's overall pipeline valuation and future revenue projections.